SCHEMBL1542858

SCHEMBL1542858

CCCCCCCCCCCCCCCCC[C](O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.60
PPARG P37231 7/20 0.60
PPARD Q03181 7/20 0.60
PPARA Q07869 7/20 0.60
HDAC11 Q96DB2 5/20 0.60
TSHR P16473 5/20 0.60
PTPN1 P18031 3/20 0.60
ALDH1A1 P00352 2/20 0.60
TLR2 O60603 2/20 0.60
TDP1 Q9NUW8 2/20 0.60
FABP4 P15090 2/20 0.60
KMT2A Q03164 2/20 0.60
SLC22A6 Q4U2R8 1/20 0.60
SLC22A8 Q8TCC7 1/20 0.60
MEN1 O00255 1/20 0.60
ESR1 P03372 1/20 0.60
ALOX15 P16050 1/20 0.60
PDE4A P27815 1/20 0.60
PDE3A Q14432 1/20 0.60
HSD17B10 Q99714 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4633330 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1768652 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL6507588 1.00
SCHEMBL2524053 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL3422866 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL2969247 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL7461021 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL18035657 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1685840 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL27497814 1.00 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110104084-A1 NOVEL COMPOSITIONS BASED ON ETHERS OF ALKYL POLYOSIDES AND ON ALKYL GLYCERYL ETHERS, USE THEREOF AS AN EMULSIFIER AND COSMETIC COMPOSITIONS CONTAINING SAME Societe d'Exploitation de Products Pour Les Industries Chimiques SEPPIC 2011-05-05 US disclosed
EP-2307433-A2 NOVEL COMPOSITIONS BASED ON ETHERS OF ALKYL POLYOSIDES AND ON ALKYL GLYCERYL ETHERS, USE THEREOF AS AN EMULSIFIER AND COSMETIC COMPOSITIONS CONTAINING SAME Societe D'Exploitation De Produits Pour Les Industries Chimiques Seppic (FR) 2011-04-13 EP disclosed
EP-2044096-B1 NEW SUGAR DERIVATIVES, METHOD FOR PREPARATION THEREOF, THEIR USE AS SURFACE-ACTIVE AGENTS SEPPIC SA (FR) 2010-06-16 EP disclosed
US-20100130581-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN THE UNIVERSITY OF QUEENSLAND 2010-05-27 US disclosed
US-7671118-B2 Stabilizer system for stabilizing halogen-containing polymers Chemtura Vinyl Additives, GmbH (DE) 2010-03-02 US disclosed
WO-2009153509-A2 NOVEL COMPOSITIONS BASED ON ETHERS OF ALKYL POLYOSIDES AND ON ALKYL GLYCERYL ETHERS, USE THEREOF AS AN EMULSIFIER AND COSMETIC COMPOSITIONS CONTAINING SAME SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2009-12-23 WO disclosed
US-20090209485-A1 MODULATING ANGIOGENESIS WITH NOD FACTORS SUCH AS GLUCOSAMINE OLIGOSACCHARIDES PARISH CHRISTOPHER RICHARD 2009-08-20 US disclosed
EP-2044096-A2 NEW SUGAR DERIVATIVES, METHOD FOR PREPARATION THEREOF, THEIR USE AS SURFACE-ACTIVE AGENTS SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES-SEPPIC (FR) 2009-04-08 EP disclosed
EP-2007790-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN THE UNIVERSITY OF QUEENSLAND (AU) 2008-12-31 EP disclosed
EP-1318799-B1 STABLE DOSAGE FORMS CONTAINING UBIQUINONES ABBOTT GMBH & CO KG (DE) 2008-12-03 EP disclosed
EP-1368423-A1 CHLORATE-CONTAINING STABILIZER SYSTEM WITH NITROGEN-CONTAINING SYNERGISTS FOR STABILIZING HALOGEN-CONTAINING POLYMERS Crompton Vinyl Additives GmbH (DE) 2003-12-10 EP disclosed
EP-1318799-A2 STABLE DOSAGE FORMS CONTAINING UBIQUINONES Abbott GmbH & Co. KG (DE) 2003-06-18 EP disclosed
WO-2002072684-A1 CHLORATE-CONTAINING STABILIZER SYSTEM WITH NITROGEN-CONTAINING SYNERGISTS FOR STABILIZING HALOGEN-CONTAINING POLYMERS CROMPTON VINYL ADDITIVES GMBH (DE) 2002-09-19 WO disclosed
WO-2002024184-A2 MECHANICALLY STABLE DOSAGE FORMS CONTAINING UBIQUINONES ABBOTT GMBH & CO. KG (DE) 2002-03-28 WO disclosed
EP-1101485-A1 Viscosity stabilized compositions comprising a zeolite and a solid fatty alcohol AVON PRODUCTS, INC. (US) 2001-05-23 EP disclosed
US-5066648-A Transdermal drug delivery, viricides, enzyme inhibitors MERCK & CO., INC. (US) 1991-11-19 US disclosed
US-4970206-A TRANSDERMAL DRUG DELIVERY MERCK & CO., INC. (US) 1990-11-13 US disclosed
US-4847250-A HYPOTENSIVE AGENTS MERCK & CO., INC. (US) 1989-07-11 US disclosed
US-4762851-A ANTIINFLAMMATORY AGENTS MERCK & CO., INC. (US) 1988-08-09 US disclosed
EP-0227531-A2 Pyroglutamic acid esters used as dermal penetration enhancers for drugs MERCK & CO. INC. (US) 1987-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130581-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN OPRL1, CRH, OPRK1 GPR84 648/4885PPARG 1906/4885PPARD 2000/4885
US-20110104084-A1 NOVEL COMPOSITIONS BASED ON ETHERS OF ALKYL POLYOSIDES AND ON ALKYL GLYCERYL ETHERS, USE THEREOF AS AN EMULSIFIER AND COSMETIC COMPOSITIONS CONTAINING SAME TYR, GK, UGCG GPR84 714/4885PPARG 66/4885PPARD 670/4885
US-20090209485-A1 MODULATING ANGIOGENESIS WITH NOD FACTORS SUCH AS GLUCOSAMINE OLIGOSACCHARIDES FLT4, UGGT1, FLT1 GPR84 506/4885PPARG 1632/4885PPARD 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.